All Over For Servier's Autism Ambitions
Neurochlore-Partnered Bumetanide Fails in Phase III
Executive Summary
The diuretic bumetanide had shown potential to improve the core symptoms of children and adolescents with autism in small studies but has failed to demonstrate any sign of effectiveness in two late-stage trials.